Novartis' Enerzair Breezhaler (QVM149- IND/GLY/MF) Receives CHMP's Recommendation for Approval as a Treatment for Uncontrolled Asthma
Shots:
- The CHMP’s recommendation is based on P-III IRIDIUM study assessing IND/GLY/MF (150/50/160 μg & 150/50/80 μg) vs IND/MF doses (150/320 μg & 150/160 μg) in 3-092 patients in a ratio (1:1:1) with uncontrolled asthma- as determined by pulmonary function testing and effects on asthma control
- The P-III IRIDIUM study resulted in improvements in lung function and ACQ-7 score. Both the treatment showed improvement in symptoms @26wks. but 2EPs was not met. In the secondary analyses- therapy showed a reduction in mod.-to-sev. and sev. asthma exacerbation rate with high-dose IND/GLY/MF vs high-dose Sal/Flu
- Novartis is working with multiple regulatory authorities- including Switzerland- Japan and Canada to bring IND/GLY/MF and IND/MF to patients. QVM149 will be administered via the dose confirming Breezhaler device- if approved- it will be the first asthma treatment that can be prescribed together with a digital companion with app and a sensor in the EU
Click here to read full press release/ article
Ref: Novartis | Image: Novartis
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com